Article Sidebar
Published:
Jun 25, 2024Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Establishment of a failure mode and effects analysis for high-risk breviscapine-based traditional Chinese medicine injection
Abstract
Purpose: To assess the failure modes and effects of clinical application of breviscapine-based traditional Chinese medicine injection (TCMI).
Methods: 229 reports on clinical application errors, medication errors or management measures relating to breviscapine injection were collected by searching various databases. A clinical application and safety evaluation questionnaire was formulated for use in the failure mode and effects analysis (FMEA) of breviscapine injection. The questionnaire survey was then distributed to 100 doctoral, nursing and pharmaceutical personnel in Xinxiang Central Hospital who were randomly chosen to participate.
Results: A total of 81 (83.5 %) valid questionnaires were retrieved. A total of 29 potential failure types, failure causes and failure effects were identified. Mean values of all risk priority numbers (RPN) of the 29 failure modes were ranked comprehensively. The failure modes identified as top 10 risk factors include; detailed information regarding the patient’s medical, allergy and family disease history not being provided to physicians (75.22); incorrect choice of drug manufacturer and lot number (74.95), drugs not being dispensed on the spot (72.16); inappropriate choice of solvent (71.31); drugs not suitable for combination therapy (70.81); inappropriate choice of solvent dosage (69.14); individual patient differences not taken into consideration (67.07); infusion rate too fast (67.00); off-label drug use (65.32); and age of the patient not taken into consideration (64.96).
Conclusion: As a risk management tool, the FMEA conducted in this study reduces potentially dangerous clinical application of high-risk TCMI, standardizes the medication process and significantly reduces occurrence of adverse reactions to TCMI. Future studies are required to validate these claims.
